Theravance Biopharma, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Less: Net income from discontinued operations
Net loss from continuing operations
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization
Amortization and accretion on investment securities, net
Future royalty payment contingency interest accretion
Share-based compensation
Gain on sale of Velusetrag
Loss on disposal of property and equipment
Loss on impairment of long-lived assets
Amortization of right-of-use assets
Gain from lease modification
Undistributed earnings from TRC, LLC
Interest shortfall on 2035 notes, net
Deferred income taxes
Other
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements
Prepaid clinical and development services
Other prepaid and current assets
Right-of-use lease assets
Future contingent milestone and royalty assets
Other assets
Accounts payable
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities
Accrued interest payable
Deferred revenue
Operating lease liabilities
Unrecognized tax benefits
Other long-term liabilities

Net cash used in operating activities - continuing operations
Net cash used in operating activities - discontinued operations
Net cash provided by (used in) operating activities

Investing activities
Purchases of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Purchase of derivative
Sale of short-term investments and marketable securities
Proceeds from the sale of Velusetrag
Proceeds from the sale of property and equipment
Net cash (used in) provided by investing activities - continuing operations
Net cash provided by investing activities - discontinued operations
Net cash (used in) provided by investing activities

Financing activities
Ordinary share repurchases
Proceeds from ampreloxetine funding, net
Proceeds from the sale of ordinary shares
Proceeds from ESPP purchases
Proceeds from option exercises
Repurchase of shares to satisfy tax withholding
Net cash used in financing activities - continuing operations
Net cash used in financing activities - discontinued operations
Net cash used in financing activities

Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes, net

Recognition of tenant improvement allowance assigned to sublease
Sublease
Total recognition of tenant improvement allowance assigned to sublease

Comments